JP2013523656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523656A5 JP2013523656A5 JP2013501523A JP2013501523A JP2013523656A5 JP 2013523656 A5 JP2013523656 A5 JP 2013523656A5 JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013523656 A5 JP2013523656 A5 JP 2013523656A5
- Authority
- JP
- Japan
- Prior art keywords
- hcc
- combination
- composition
- nanoparticles
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 37
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 229940123237 Taxane Drugs 0.000 claims description 12
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 12
- 102100027211 Albumin Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 101000831940 Homo sapiens Stathmin Proteins 0.000 claims description 6
- 108091022875 Microtubule Proteins 0.000 claims description 6
- 102000029749 Microtubule Human genes 0.000 claims description 6
- 102100024237 Stathmin Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000004688 microtubule Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 102100028247 Abl interactor 1 Human genes 0.000 claims description 2
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims description 2
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims description 2
- 102000017925 CHRM3 Human genes 0.000 claims description 2
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 claims description 2
- 102100033592 Calponin-3 Human genes 0.000 claims description 2
- 102000011068 Cdc42 Human genes 0.000 claims description 2
- 102100028633 Cdc42-interacting protein 4 Human genes 0.000 claims description 2
- 102100024351 Dedicator of cytokinesis protein 7 Human genes 0.000 claims description 2
- 102100031477 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Human genes 0.000 claims description 2
- 101710167313 Drebrin-like protein Proteins 0.000 claims description 2
- 102100028570 Drebrin-like protein Human genes 0.000 claims description 2
- -1 ERLF1 Proteins 0.000 claims description 2
- 102100036825 Erythroid membrane-associated protein Human genes 0.000 claims description 2
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 claims description 2
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims description 2
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 claims description 2
- 101000724225 Homo sapiens Abl interactor 1 Proteins 0.000 claims description 2
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 claims description 2
- 101000945410 Homo sapiens Calponin-3 Proteins 0.000 claims description 2
- 101000766830 Homo sapiens Cdc42-interacting protein 4 Proteins 0.000 claims description 2
- 101001052952 Homo sapiens Dedicator of cytokinesis protein 7 Proteins 0.000 claims description 2
- 101001130785 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Proteins 0.000 claims description 2
- 101000851733 Homo sapiens Erythroid membrane-associated protein Proteins 0.000 claims description 2
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 claims description 2
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 claims description 2
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 claims description 2
- 101000923835 Homo sapiens Low density lipoprotein receptor adapter protein 1 Proteins 0.000 claims description 2
- 101000928919 Homo sapiens Muscarinic acetylcholine receptor M3 Proteins 0.000 claims description 2
- 101000597499 Homo sapiens Obg-like ATPase 1 Proteins 0.000 claims description 2
- 101000596046 Homo sapiens Plastin-2 Proteins 0.000 claims description 2
- 101000877404 Homo sapiens Protein enabled homolog Proteins 0.000 claims description 2
- 101000983130 Homo sapiens Protein kinase C and casein kinase substrate in neurons protein 2 Proteins 0.000 claims description 2
- 101000615238 Homo sapiens Proto-oncogene DBL Proteins 0.000 claims description 2
- 101100078258 Homo sapiens RUNX1T1 gene Proteins 0.000 claims description 2
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims description 2
- 101001106403 Homo sapiens Rho GTPase-activating protein 4 Proteins 0.000 claims description 2
- 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 claims description 2
- 101000762938 Homo sapiens TOX high mobility group box family member 4 Proteins 0.000 claims description 2
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 claims description 2
- 102100034389 Low density lipoprotein receptor adapter protein 1 Human genes 0.000 claims description 2
- 102100035415 Obg-like ATPase 1 Human genes 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100035182 Plastin-2 Human genes 0.000 claims description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 2
- 102100035093 Protein enabled homolog Human genes 0.000 claims description 2
- 102100026843 Protein kinase C and casein kinase substrate in neurons protein 2 Human genes 0.000 claims description 2
- 102100021384 Proto-oncogene DBL Human genes 0.000 claims description 2
- 108700040655 RUNX1 Translocation Partner 1 Proteins 0.000 claims description 2
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims description 2
- 102100021431 Rho GTPase-activating protein 4 Human genes 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 102100028051 Stathmin-2 Human genes 0.000 claims description 2
- 108010040632 Transforming Protein 2 Src Homology 2 Domain-Containing Proteins 0.000 claims description 2
- 102000002016 Transforming Protein 2 Src Homology 2 Domain-Containing Human genes 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 102100036788 Tubulin beta-4A chain Human genes 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims description 2
- 230000000683 nonmetastatic effect Effects 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 claims 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31815310P | 2010-03-26 | 2010-03-26 | |
| US61/318,153 | 2010-03-26 | ||
| PCT/US2011/030037 WO2011119988A1 (en) | 2010-03-26 | 2011-03-25 | Methods of treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Division JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523656A JP2013523656A (ja) | 2013-06-17 |
| JP2013523656A5 true JP2013523656A5 (Direct) | 2014-05-08 |
| JP5847156B2 JP5847156B2 (ja) | 2016-01-20 |
Family
ID=44673662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501523A Active JP5847156B2 (ja) | 2010-03-26 | 2011-03-25 | 肝細胞がんの処置方法 |
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9370494B2 (Direct) |
| EP (2) | EP2898884B1 (Direct) |
| JP (2) | JP5847156B2 (Direct) |
| KR (1) | KR101786142B1 (Direct) |
| CN (2) | CN103052385B (Direct) |
| AU (1) | AU2011230512B2 (Direct) |
| BR (1) | BR112012024349A2 (Direct) |
| CA (2) | CA2793536C (Direct) |
| DK (1) | DK2552438T3 (Direct) |
| ES (2) | ES2580135T3 (Direct) |
| HR (1) | HRP20160609T1 (Direct) |
| HU (1) | HUE027749T2 (Direct) |
| IL (2) | IL221886A (Direct) |
| LT (1) | LT2552438T (Direct) |
| MX (2) | MX346861B (Direct) |
| NZ (1) | NZ602382A (Direct) |
| PL (1) | PL2552438T3 (Direct) |
| PT (1) | PT2552438T (Direct) |
| TW (1) | TWI495467B (Direct) |
| WO (1) | WO2011119988A1 (Direct) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| MX383644B (es) | 2005-02-18 | 2025-03-14 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| EP2117520B1 (en) | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| EP3626233A1 (en) | 2009-04-15 | 2020-03-25 | Abraxis BioScience, LLC | Prion-free nanoparticle compositions and methods |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| KR20180050426A (ko) | 2010-03-29 | 2018-05-14 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
| KR20140107417A (ko) | 2011-12-14 | 2014-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014159171A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| EP3003288A1 (en) | 2013-05-30 | 2016-04-13 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| US20150247204A1 (en) * | 2014-02-07 | 2015-09-03 | The General Hopital Corporation | Differential diagnosis of hepatic neoplasms |
| PT3223796T (pt) | 2014-11-25 | 2021-09-28 | Curadigm Sas | Composições farmacêuticas, preparação e suas utilizações |
| AR102778A1 (es) * | 2014-11-25 | 2017-03-22 | Nanobiotix | Composición farmacéutica, su preparación y sus usos |
| LT3229776T (lt) | 2014-11-25 | 2023-08-25 | Curadigm Sas | Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas |
| LT3236934T (lt) | 2014-11-25 | 2024-08-26 | Curadigm Sas | Farmacinė kompozicija, preparatas ir jo panaudojimas |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| CN107708668A (zh) | 2015-05-28 | 2018-02-16 | 纳米生物技术公司 | 用作治疗性疫苗的纳米粒子 |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| EP3522887A4 (en) * | 2016-10-07 | 2020-06-10 | Abraxis BioScience, LLC | METHODS OF TREATING BILARIAN CANCER |
| WO2018081520A1 (en) | 2016-10-27 | 2018-05-03 | Zhuhai Beihai Biotech Co., Ltd. | Neutral ph compositions of docetaxel and human serum albumin |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CN107828887A (zh) * | 2017-10-12 | 2018-03-23 | 上海市东方医院 | Stmn1基因的用途 |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| JP2024542042A (ja) * | 2021-10-26 | 2024-11-13 | リポジェムス・インターナショナル・エッセ・ピ・ア | 肝がん療法での薬物送達システムとしての微小断片化脂肪組織 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| ES2219646T5 (es) | 1993-02-22 | 2008-11-01 | Abraxis Bioscience, Inc. | Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos. |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| KR100789008B1 (ko) | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | 신규 약물 제제 |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
| EP1178786A4 (en) | 1999-05-21 | 2006-03-01 | American Bioscience Inc | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE |
| GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| WO2004052401A2 (en) | 2002-12-09 | 2004-06-24 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| MX383644B (es) | 2005-02-18 | 2025-03-14 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
| BRPI0615265A8 (pt) * | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス， エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| AU2006347740A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP2076599A2 (en) * | 2006-09-19 | 2009-07-08 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| EP2117520B1 (en) | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| EP2146735B1 (en) | 2007-04-13 | 2012-06-20 | Abraxis BioScience, Inc. | Compositions comprising sparc polypeptides |
| CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
| US20120128732A1 (en) | 2008-12-11 | 2012-05-24 | Vuong Trieu | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP5725563B2 (ja) | 2009-03-13 | 2015-05-27 | アブラクシス バイオサイエンス， エルエルシー | チオコルヒチン誘導体との組み合わせ療法 |
| MX2011010673A (es) | 2009-04-10 | 2012-02-21 | Abraxis Bioscience Llc | Formulaciones de nanoparticulas y usos de las mismas. |
| EP3626233A1 (en) | 2009-04-15 | 2020-03-25 | Abraxis BioScience, LLC | Prion-free nanoparticle compositions and methods |
| DK2470173T3 (en) | 2009-08-25 | 2016-06-06 | Abraxis Bioscience Llc | Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| KR20180050426A (ko) | 2010-03-29 | 2018-05-14 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| ES2639038T3 (es) | 2010-06-02 | 2017-10-25 | Abraxis Bioscience, Llc | Métodos para el tratamiento de cáncer de vejiga |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| RU2016103126A (ru) | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
| CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
| KR20140107417A (ko) | 2011-12-14 | 2014-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2011
- 2011-03-25 ES ES11760333.2T patent/ES2580135T3/es active Active
- 2011-03-25 AU AU2011230512A patent/AU2011230512B2/en active Active
- 2011-03-25 EP EP14200645.1A patent/EP2898884B1/en active Active
- 2011-03-25 EP EP11760333.2A patent/EP2552438B1/en active Active
- 2011-03-25 LT LTEP11760333.2T patent/LT2552438T/lt unknown
- 2011-03-25 JP JP2013501523A patent/JP5847156B2/ja active Active
- 2011-03-25 DK DK11760333.2T patent/DK2552438T3/en active
- 2011-03-25 CN CN201180025949.1A patent/CN103052385B/zh active Active
- 2011-03-25 BR BR112012024349A patent/BR112012024349A2/pt not_active Application Discontinuation
- 2011-03-25 US US13/583,603 patent/US9370494B2/en active Active
- 2011-03-25 KR KR1020127027815A patent/KR101786142B1/ko active Active
- 2011-03-25 HU HUE11760333A patent/HUE027749T2/en unknown
- 2011-03-25 CA CA2793536A patent/CA2793536C/en active Active
- 2011-03-25 CA CA3051495A patent/CA3051495A1/en not_active Abandoned
- 2011-03-25 PL PL11760333.2T patent/PL2552438T3/pl unknown
- 2011-03-25 CN CN201510242264.2A patent/CN104784121A/zh active Pending
- 2011-03-25 MX MX2012010936A patent/MX346861B/es active IP Right Grant
- 2011-03-25 NZ NZ602382A patent/NZ602382A/en unknown
- 2011-03-25 PT PT117603332T patent/PT2552438T/pt unknown
- 2011-03-25 MX MX2016015444A patent/MX359413B/es unknown
- 2011-03-25 HR HRP20160609TT patent/HRP20160609T1/hr unknown
- 2011-03-25 WO PCT/US2011/030037 patent/WO2011119988A1/en not_active Ceased
- 2011-03-25 ES ES14200645.1T patent/ES2675212T3/es active Active
- 2011-03-28 TW TW100110703A patent/TWI495467B/zh active
-
2012
- 2012-09-11 IL IL221886A patent/IL221886A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,480 patent/US20140079787A1/en not_active Abandoned
-
2015
- 2015-04-28 JP JP2015091142A patent/JP2015134825A/ja active Pending
-
2016
- 2016-05-20 US US15/160,598 patent/US20160374952A1/en not_active Abandoned
- 2016-08-08 IL IL247171A patent/IL247171B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523656A5 (Direct) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2013503174A5 (Direct) | ||
| JP2015134825A5 (Direct) | ||
| Chen et al. | Autophagy and doxorubicin resistance in cancer | |
| JP2010514787A5 (Direct) | ||
| JP2013527233A5 (Direct) | ||
| RU2012156275A (ru) | Способ и лечение рака поджелудочной железы | |
| Provencio et al. | New molecular targeted therapies integrated with radiation therapy in lung cancer | |
| JP2010509331A5 (Direct) | ||
| JP2013527232A5 (Direct) | ||
| JP2015533176A5 (Direct) | ||
| WO2007139930A3 (en) | Drug combinations with substituted diaryl ureas for the treatment of cancer | |
| JP2019529520A5 (Direct) | ||
| Brogdon et al. | Development of other microtubule-stabilizer families: the epothilones and their derivatives | |
| JP2016505018A5 (Direct) | ||
| JP2016536352A5 (Direct) | ||
| WO2007069272A3 (en) | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer | |
| JP2019521180A5 (Direct) | ||
| JP2016515586A5 (Direct) | ||
| Lee et al. | Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced Non–small-cell lung cancer: a multicenter randomized phase IIB trial | |
| Awada et al. | Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours | |
| JP2018536655A5 (Direct) | ||
| Zhou et al. | Circular RNA-regulated autophagy is involved in cancer progression | |
| Safra et al. | Weekly Paclitaxel with Intermittent Imatinib Mesylate (Gleevec®>): Tolerance and Activity in Recurrent Epithelial Ovarian Cancer |